Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos, sex toys and adult toys.
Popular Articles

Research Into Genetic Neurological Disorders Will Benefit From New Mouse Model
Neurosensory diseases are difficult to model in mice because their symptoms are complex and diverse. The genetic causes identified are often lethal when transferred to a mouse. The lack of animal models slows progress in understanding and treating the diseases. By strategically altering a protein-making molecule, a mouse was made to help understand nervous system diseases that impair feeling and cause paralysis of the arms and legs in humans.
buy viagra
New Study Measures Benefits Of More Involved Fathers
Family service agencies are missing huge opportunities to help children by focusing only on mothers and ignoring fathers, according to a groundbreaking study by some of the nation"s top family and child development researchers.
plan for health
News of the day
Somaxon Resubmits New Drug Application For Silenor(R) (Doxepin) For The Treatment Of Insomnia
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Silenor® (doxepin) for the treatment of insomnia.
Diagnostics

Promedior Initiates Phase 1 Clinical Trial Of PRM-151, A Novel Compound For The Treatment Of Fibrotic Diseases And Tissue Remodeling

Promedior, Inc. announced the initiation of a Phase 1 clinical trial of PRM-151, a novel compound in development for the treatment of fibrotic diseases and tissue remodeling. The Phase 1 dose escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of ascending single intravenous doses of PRM-151 in healthy subjects. The study is being conducted at the Centre for Human Drug Research in The Netherlands. PRM-151(rhSAP) is a recombinant form of human Serum Amyloid P, a highly conserved natural human protein that mediates its anti-fibrotic activity by targeting the specific cell populations that orchestrate fibrosis and tissue remodeling. PRM-151 has demonstrated an outstanding preclinical safety profile and robust preclinical efficacy by reducing fibrosis in multiple tissues, organs, and disease models. "The initiation of the Phase 1 clinical trial of PRM-151 represents an important milestone in the development of Promedior"s novel platform of products for the treatment of fibrotic diseases," said Dominick Colangelo, Chief Executive Officer of Promedior. "We believe that PRM-151 has tremendous potential to play an important role in improving patient outcomes across multiple disease indications and will position Promedior in a leadership position in the development of innovative anti-fibrotic therapeutics." "Through its fundamental role in regulating monocyte responses to injured tissue, we believe PRM-151 affects a common biology present in all forms of pathologic fibrosis," commented Dr. Mark Lupher, Jr., the company"s Senior Vice President of Discovery Research. "In collaboration with leading investigators at Harvard University, Yale University, University of Michigan, University of California San Diego and Rice University, we have consistently demonstrated significant anti-fibrotic activity across model systems, including in established disease settings, and are very excited to advance this novel compound into clinical research." Promedior, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009